Good earning for Q4,2012 and Q1,2013 will even be better.
--Pacb has 71 sequencers on market with uptime of 90%, better then Q3 quarter on 50% uptime.
--Six new sequencers (600K per sequencer) order in Q4. Better then Q3 of 5 sequencers.
--Q4 revenue doubled from Q3,2012. 50% lower then Q4, 2011, I think this is because they are spending lot up R&D and upgrade.
--Best thing, users are very happy about Long pacbio reads.
--Q1 result will be even better but I'm not sure about Q3 because it depends on NIH and other research budget. I think even with budget cuts pacbio will do better because researchers want long reads rather then lots of short reads.
-Pacbio doubled the run capacity and improved read accuracy to 99.9999% using HGAP and Quiver algorithms to correct long reads.